Gan Lee Presents P-I Results of Proposed Biosimilar Insulins Aspart, Lispro and Glargine at ADA 2021

July 5, 2021 Auto Bot Biosimilars, Clinical Trials, Gan & Lee, Proposed Biosimilar 0

Shots:

  • The company reported that all the P-I studies assessing insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA) met their primary PK & PD analyses and demonstrated that PK/PD bioequivalence b/w each of the proposed biosimilar and their respective reference compounds
  • The safety profiles were comparable b/w each of the three proposed biosimilar and their respective reference compounds
  • The company is working to bring biosimilar insulins into clinical practice with the goal of reducing the global burden of diabetes

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Caixin Global

The post Gan Lee Presents P-I Results of Proposed Biosimilar Insulins Aspart, Lispro and Glargine at ADA 2021 first appeared on PharmaShots.